Profile data is unavailable for this security.
About the company
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
- Revenue in USD (TTM)20.97m
- Net income in USD-118.51m
- Incorporated2004
- Employees55.00
- LocationCara Therapeutics Inc400 Atlantic Street, Suite 500STAMFORD 06901United StatesUSA
- Phone+1 (203) 406-3700
- Fax+1 (203) 567-1510
- Websitehttps://www.caratherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eyenovia Inc | 3.79k | -27.26m | 36.25m | 57.00 | -- | 3.60 | -- | 9,563.68 | -0.6639 | -0.6639 | 0.00009 | 0.1976 | 0.0001 | -- | 0.0031 | 66.49 | -91.15 | -80.31 | -119.11 | -117.70 | 0.00 | -- | -719,290.30 | -680.95 | 2.16 | -15.14 | 0.6135 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 36.36m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
Incannex Healthcare Inc | 163.39k | -13.70m | 36.51m | -- | -- | 1.93 | -- | 223.44 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
Promis Neurosciences Inc | 0.00 | -13.21m | 36.97m | 6.00 | -- | 9.81 | -- | -- | -1.22 | -1.22 | 0.00 | 0.1987 | 0.00 | -- | -- | 0.00 | -128.63 | -144.28 | -552.70 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
SAB Biotherapeutics Inc | 2.24m | -42.19m | 36.99m | 57.00 | -- | 0.6456 | -- | 16.52 | -7.18 | -7.18 | 0.4056 | 6.21 | 0.0332 | -- | 0.8059 | 39,280.53 | -62.58 | -- | -77.39 | -- | -- | -- | -1,884.50 | -- | -- | -- | 0.0743 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
Cyclo Therapeutics Inc | 1.08m | -20.06m | 37.04m | 8.00 | -- | 7.74 | -- | 34.41 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
Estrella Immunopharma Inc | 0.00 | -2.16m | 38.08m | -- | -- | 3.64 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
Ocuphire Pharma Inc | 19.05m | -9.99m | 38.09m | 14.00 | -- | 0.7375 | -- | 2.00 | -0.4735 | -0.4735 | 0.8727 | 2.08 | 0.3701 | -- | 5.30 | 1,360,643.00 | -19.40 | -58.31 | -20.77 | -65.94 | -- | -- | -52.42 | -137.92 | -- | -8.46 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
Cara Therapeutics Inc | 20.97m | -118.51m | 38.26m | 55.00 | -- | 0.6681 | -- | 1.82 | -2.19 | -2.19 | 0.3872 | 1.05 | 0.1361 | 2.37 | 6.96 | 381,236.40 | -76.94 | -35.76 | -91.50 | -40.82 | 70.56 | -- | -565.21 | -162.10 | 4.43 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Marker Therapeutics Inc | 3.31m | -14.05m | 38.86m | 8.00 | -- | 2.76 | -- | 11.74 | -1.59 | -0.933 | 0.3753 | 1.58 | 0.1285 | -- | 1.93 | 413,892.50 | -54.49 | -53.74 | -69.03 | -62.25 | -- | -- | -424.20 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
Benson Hill Inc | 473.34m | -111.25m | 39.18m | 270.00 | -- | 0.4553 | -- | 0.0828 | -0.5914 | -0.6131 | 2.52 | 0.4129 | 1.22 | 10.27 | 14.81 | 1,753,096.00 | -28.68 | -- | -38.28 | -- | 4.99 | 3.18 | -23.50 | -40.73 | 0.9166 | -2.33 | 0.4509 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
Natural Alternatives International, Inc. | 127.76m | -4.11m | 39.39m | 317.00 | -- | 0.461 | 87.54 | 0.3083 | -0.705 | -0.705 | 21.87 | 14.03 | 0.8624 | 4.23 | 12.32 | 403,041.00 | -2.77 | 4.90 | -3.11 | 5.93 | 7.90 | 15.98 | -3.22 | 3.80 | 2.59 | -2.54 | 0.0988 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
ImmuCell Corp | 17.47m | -5.77m | 39.53m | 79.00 | -- | 1.58 | -- | 2.26 | -0.7454 | -0.7454 | 2.26 | 3.22 | 0.3941 | 1.96 | 8.86 | 221,160.40 | -13.03 | -5.16 | -14.19 | -5.53 | 22.15 | 40.04 | -33.05 | -12.64 | 0.8715 | -15.17 | 0.3238 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Carmell Corp | 0.00 | -16.88m | 40.22m | 9.00 | -- | 1.95 | -- | -- | -1.53 | -1.46 | 0.00 | 1.07 | -- | -- | -- | 0.00 | -- | -- | -- | -- | 58.60 | -- | -- | -- | -- | -194.46 | 0.0495 | -- | -- | -- | -75.70 | -- | -- | -- |
Janone Inc | 0.00 | -17.10m | 40.48m | 5.00 | -- | -- | -- | -- | -3.52 | -0.4564 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.40 | -23.12 | -96.58 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.0594 | -- | -- | -- | -313.15 | -- | -- | -- |
Aspira Women's Health Inc | 9.15m | -16.69m | 40.49m | 64.00 | -- | -- | -- | 4.42 | -1.73 | -1.73 | 0.9683 | -0.2222 | 0.7746 | 14.34 | 6.77 | 143,031.30 | -141.23 | -110.58 | -256.99 | -151.88 | 57.48 | 45.23 | -182.32 | -334.08 | 0.9871 | -- | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 3.18m | 5.83% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.59m | 4.74% |
Disciplined Growth Investors, Inc.as of 31 Dec 2023 | 1.81m | 3.32% |
Chescapmanager LLCas of 31 Dec 2023 | 1.75m | 3.21% |
Farallon Capital Management LLCas of 31 Dec 2023 | 1.56m | 2.85% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.02m | 1.87% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.01m | 1.85% |
Federated MDTA LLCas of 31 Dec 2023 | 831.85k | 1.52% |
AQR Capital Management LLCas of 31 Dec 2023 | 828.80k | 1.52% |
Renaissance Technologies LLCas of 31 Dec 2023 | 697.03k | 1.28% |